|
|
Psoriasis and the metabolic syndrome.(Clinical report)
- Article from:
-
Journal of Drugs in Dermatology
- Article date:
-
June 1, 2008
- Author:
-
;
;
|
Copyright informationCOPYRIGHT 2008 Journal of Drugs in Dermatology, Inc. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
Abstract
Psoriasis is a chronic immune-inflammatory-mediated disease that can predispose patients to other inflammatory conditions. For example, individuals with psoriasis are at increased risk for insulin resistance, obesity, dyslipidemia, and hypertension-components that characterize the metabolic syndrome. The metabolic syndrome is an important driver of adverse cardiovascular outcomes. Proinflammatory cytokines, such as tumor necrosis factor-alpha (TNF-[alpha]), and other factors that are overproduced in patients with psoriasis likely contribute to the increased risk for development of metabolic syndrome. This article reviews the association of psoriasis with metabolic ...
<50 mg/dL in women
mg/dL in mg/dL in women or drug treatment
women or drugfor reduced levels
treatment for
reduced
levels
Blood pressure[greater than [greater than [greater than or
or equal to] or equal to] equal to] 130 mm Hg
140/90 mm Hg 130 mm Hg or systolic or [greater
[greater systolic than or equal to]85
than or equal mm Hg diastolic or
to]85 mm Hgdrug treatment for
diastolic or hypertension
drug treatment
for hypertension
Fasting plasmaIFG, IFG, or [greater than [greater than or
glucose type 2 DM or equal to] equal] 100 mg/dL or
100 mg/dL or drug treatment for
drug treatment DM
for DM
Microalbuminuria>
<.01) was reported for hypertension in a German cohort of patients admitted to the hospital for psoriasis compared with patients admitted for other dermatologic conditions. (36) More recently, Sommer et al (11) reported that inpatients with psoriasis had a>